List view / Grid view
4 December 2013 | By Novartis
"Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers..."
29 November 2013 | By Novartis
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria...
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
14 November 2013 | By Novartis
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant...
11 November 2013 | By Novartis
Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion...
22 October 2013 | By Novartis
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth..."
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
27 September 2013 | By Novartis
Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year...
8 September 2013 | By Novartis
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler®...
6 September 2013 | By
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need...
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
4 September 2013 | By Novartis
Robust efficacy of once-daily Ultibro® Breezhaler® (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro® LABA+LAMA combination for the treatment of COPD patients[1],[2],[3]...
